Table 2 The Vanderbilt staging system for retroperitoneal sarcoma

From: The Vanderbilt staging system for retroperitoneal sarcoma: a validation study of 6857 patients from the National Cancer Database

Stage

Description

N (%)

HR (95% CI)

P

IA

G1 T1 FH

518 (8%)

1.00

—

 

G1 T2 FH

   

IB

G1 T3 FH

1334 (20%)

1.23 (0.99–1.53)

0.065

 

G2 T1 FH

   
 

G2 T2 FH

   
 

G1 T1 UH

   

II

G2 T3 FH

1424 (21%)

2.29 (1.86–2.81)

<0.0005

 

G3 T1 FH

   
 

G3 T2 FH

   
 

G1 T2 UH

   
 

G1 T3 UH

   
 

G2 T1 UH

   
 

G2 T2 UH

   
 

G1 Tx M1

   

IIIA

G3 T3 FH

1542 (22%)

3.23 (2.64–3.95)

<0.0005

 

G2 T3 UH

   
 

G3 T1 UH

   

IIIB

G3 T2 UH

965 (14%)

4.39 (3.58–5.40)

<0.0005

 

G3 T3 UH

   

IV

G2 Tx M1

357 (5%)

8.71 (6.97–10.9)

<0.0005

 

G3 Tx M1

   

Not staged

—

717 (10%)

—

—

  1. CI confidence interval, FH favorable histology (see text for definition),
  2. G histologic grade, HR hazard ratio, M1 distant metastasis, T1 tumor size ≤ 10 cm in greatest dimension, T2 tumor size > 10 cm and ≤15 cm in greatest dimension, T3 tumor size >15 cm in greatest dimension, Tx any T category UH unfavorable histology (see text for definition)
Back to article page